Ken Griffin Uni Qure N.V. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$3.78 - $10.12 $16,254 - $43,516	-4,300 Reduced 6.6%	60,900 $300,000
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $55,752 - $68,961	12,700 Added 24.19%	65,200 $292,000
Q1 2024 May 15, 2024	SELL	$4.82 - $6.93 $27,474 - $39,501	-5,700 Reduced 9.79%	52,500 $273,000
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $67,560 - $99,240	-12,000 Reduced 17.09%	58,200 $394,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $108,031 - $190,463	16,100 Added 29.76%	70,200 $471,000
Q2 2023 Aug 14, 2023	SELL	$11.12 - $22.2 $333,600 - $666,000	-30,000 Reduced 35.67%	54,100 $619,000
Q1 2023 May 15, 2023	SELL	$18.7 - $23.07 $1.31 Million - $1.61 Million	-69,800 Reduced 45.35%	84,100 $1.69 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $76,104 - $114,744	4,200 Added 2.81%	153,900 $3.49 Million
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $443,178 - $666,594	-26,100 Reduced 14.85%	149,700 $2.81 Million

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.